(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...